Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer related death both in the United States and worldwide. Proper management begins with identification of high risk individuals who may benefit from a screening program for HCC, since early detection of this cancer can lead to improved survival. Advances in radiographic technology and new staging systems that take tumor burden and clinical status into account allow patients to be more accurately stratified into proper treatment groups. Depending on the cancer stage, treatments such as radiofrequency ablation (RFA), surgical resection and liver transplantation offer a potential cure, while other treatments such as transarterial chemoembolization (TACE) can prolong life with HCC. New agents such as the oral multikinase inhibitor sorafenib show promise of slowing disease through utilization of molecular targeting. In this article, we will review management strategies of HCC, from diagnosis to treatment.
Keywords: Hepatocellular carcinoma, therapy, liver transplantation, diagnosis
Current Cancer Therapy Reviews
Title: Current Treatment Strategies for Hepatocellular Carcinoma
Volume: 6 Issue: 3
Author(s): Andrew Aronsohn and Smruti R. Mohanty
Affiliation:
Keywords: Hepatocellular carcinoma, therapy, liver transplantation, diagnosis
Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer related death both in the United States and worldwide. Proper management begins with identification of high risk individuals who may benefit from a screening program for HCC, since early detection of this cancer can lead to improved survival. Advances in radiographic technology and new staging systems that take tumor burden and clinical status into account allow patients to be more accurately stratified into proper treatment groups. Depending on the cancer stage, treatments such as radiofrequency ablation (RFA), surgical resection and liver transplantation offer a potential cure, while other treatments such as transarterial chemoembolization (TACE) can prolong life with HCC. New agents such as the oral multikinase inhibitor sorafenib show promise of slowing disease through utilization of molecular targeting. In this article, we will review management strategies of HCC, from diagnosis to treatment.
Export Options
About this article
Cite this article as:
Aronsohn Andrew and R. Mohanty Smruti, Current Treatment Strategies for Hepatocellular Carcinoma, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698151
DOI https://dx.doi.org/10.2174/157339410791698151 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Leptin in Non-Autoimmune Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) A Review of the Relationships Between Endogenous Sex Steroids and Incident Ischemic Stroke and Coronary Heart Disease Events
Current Cardiology Reviews Editorial Statins: [Hot Topic: Statins: Effects Beyond Cholesterol Lowering (Guest Editor: Garry X. Shen)]
Current Drug Targets - Cardiovascular & Hematological Disorders Pathogenesis and Clinical Features of Obesity and Insulin Resistance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti-VEGF Treatment of Glaucoma
Current Drug Therapy Bile Acids and Farnesoid X Receptor: Novel Target for the Treatment of Diabetic Cardiomyopathy
Current Protein & Peptide Science Challenges and Controversies in Autoantibodies Associated with Systemic Rheumatic Diseases
Current Rheumatology Reviews Effect of the NMDA-Receptor Antagonist Dextromethorphan in Infant Rat Pneumococcal Meningitis
Current Drug Metabolism Inducible Nitric Oxide Synthase as a Possible Target in Hypertension
Current Drug Targets Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Asymmetric Dimethylarginine (ADMA) and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Involvement of Dietary Bioactive Proteins and Peptides in Autism Spectrum Disorders
Current Protein & Peptide Science Anthracycline-Induced Cardiotoxicity
Cardiovascular & Hematological Agents in Medicinal Chemistry Risk Stratification in Pulmonary Embolism
Current Respiratory Medicine Reviews Angiogenesis Inhibition in the Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Cord Blood as Diagnostic Window for Preeclampsia
Recent Patents on Biomarkers Statins in Aortic Disease
Current Pharmaceutical Design Editorial [Hot Topic:Metalloproteinases Revisited (Guest Editor: Marcia L. Moss)]
Current Pharmaceutical Biotechnology Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Olmesartan Reduces Pentosidine Production and Ameliorates Fragility of Bone in Ovariectomized Fructose-Fed Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)